As advanced therapy technology and manufacturing evolve, there are three key operational challenges to address unique to these products.
Erin Finot
Advertisement
Articles by Erin Finot
Erin Finot, Global Head of Immuno-Oncology at IQVIA Biotech, discusses the immense challenges to overcome before advanced therapies become more widespread.
Advertisement
Latest Updated Articles
Top Three Sources of Operational Complexity in Cell and Gene Therapy Clinical TrialsPublished: September 4th 2019 | Updated:
- Operational Complexity in Cell and Gene Therapy Trials
Published: October 1st 2019 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
How IQVIA and Veeva Are Improving Efficiency and Data Management in Clinical Trials
2
ACT Brief Weekly Recap: Partnerships, Site Networks, and AI Reshaping Clinical Trials
3
Ipsen’s IPN10200 Demonstrates Long-Lasting Efficacy in Phase II LANTIC Trial for Glabellar Lines
4
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
